As IL‐1α driven inflammatory activation of fibroblasts could be partially reduced by dexamethasone, anti‐IL‐1α compounds could be a potential anti‐inflammatory therapy for transplant patients who developed BOS that is unresponsive to azithromycin. The gene discussed is IL1A; the disease is Buschke-Ollendorff syndrome.